COMPANY PROFILE

LevitasBio

Explore full profile

Redefining cellular analytics with its novel platform magnetic levitation technology

San Francisco, United StatesFounded 2017Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2022

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About LevitasBio

LevitasBio is a pioneering company in the biotechnology sector, specializing in advanced cell separation technologies. The company serves a diverse range of clients, including academic researchers, pharmaceutical companies, and clinical laboratories. Operating in the life sciences market, LevitasBio's core business model revolves around providing cutting-edge tools that enable researchers to work with a variety of cell samples, from simple to complex. The company's flagship product leverages unique levitation technology to enrich viable cells, remove debris, and optimize sample quality, thereby enhancing the accuracy and efficiency of downstream applications such as single-cell genomics and flow cytometry. LevitasBio generates revenue through the sale of its proprietary instruments and consumables, as well as through service contracts and collaborations with research institutions. By significantly reducing the time and cost associated with cell preparation, LevitasBio's solutions offer substantial value to its clients, driving productivity and innovation in biological research.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: San Francisco, United States
Employees: 28
Open positions: 1
Dealroom signal: 61.0/100
Industry: Health, Transportation
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Eitclimatecleantech, Vehicles, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning LevitasBio.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Nov 2022	$35M	$140M	Decheng Capital · Novalis Lifesciences · Pavilion Capital	↗
SERIES BOther financing	Jan 2021	$18M	$72M	Decheng Capital	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

LevitasBio website traffic

Latest recorded traffic for LevitasBio is 1.3K monthly website visits, down 51.9% over the last three months. LevitasBio's team declined 17.6% over the past year.

Latest monthly visits1.3K 3-month web change-51.9% 1-year team growth-17.6%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MLMitotype Precision LabsHigh-throughput mitochondrial assays for drug discovery	Sheffield, United Kingdom	Operational	8	$1.4M	$3.3M
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational
SPSpireaAdvanced antibody-drug conjugate technology for cancer therapeutics	Harrogate, United Kingdom	Operational
LBLeucid BioNext-generation CAR-T cell therapies for refractory cancers	London, United Kingdom	Operational
DADJS AntibodiesAntibody therapeutics for chronic inflammatory and fibrotic diseases	Oxford, United Kingdom	Acquired
RERenovosNanoclay gel platform for regenerative medicine therapeutics	Chilworth, United Kingdom	Operational
ATArgonaut TherapeuticsDeveloping epigenetic therapies targeting abnormal arginine methylation	Oxford, United Kingdom	Acquired
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational